Updates are available Correction dated 2021-07-23

Article History

Received: 21 February 2019

Accepted: 20 August 2019

First Online: 7 September 2019

Change Date: 23 July 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00432-021-03737-w

Compliance with ethical standards

:

: Dr. Kirita reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chugai Pharmaceutical, personal fees from MSD, personal fees from Novartis Pharma, personal fees from Pfizer, personal fees from Roche, and personal fees from Boston, outside the submitted work. Dr. Udagawa reports personal fees from AstraZeneca, grants and personal fees from MSD, personal fees from Taiho, personal fees from Amco, grants and personal fees from AbbVie, personal fees from Chugai Pharmaceutical, personal fees from Bristol-Myers Squibb, personal fees from Ono Pharmaceutical, grants from Daiichi Sankyo, and grants from AMGEN, outside the submitted work. Dr. Matsumoto reports grants from Chugai Pharmaceutical Co., Ltd., grants from Novartis Pharma K.K., and grants from Merck Serono Co., Ltd., outside the submitted work. Dr. Yoh reports grants and personal fees from Ono Pharmaceutical, grants and personal fees from Taiho Pharmaceutical, grants and personal fees from Chugai Pharma, grants and personal fees from AstraZeneca, grants and personal fees from Lilly Japan, personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, grants from Pfizer, grants and personal fees from MSD, grants from Bristol-Myers Squibb, and grants from Bayer, outside the submitted work. Dr. Niho reports personal fees from Bristol-Myers Squibb, personal fees from MSD, personal fees from Chugai, grants and personal fees from AstraZeneca, grants from Merck Serono, and grants and personal fees from Pfizer, outside the submitted work. Dr. Goto reports grants and personal fees from Eli Lilly, during the conduct of the study; grants and personal fees from AbbVie Stemcentrx, grants from Ignyta, personal fees from F. Hoffmann-La Roche, grants and personal fees from Life Technologies Japan, grants from Oxonc, personal fees from Otsuka Pharmaceutical, grants and personal fees from RIKEN GENESIS, personal fees from SRL, grants and personal fees from Sumitomo Dainippon Pharma, grants and personal fees from AstraZeneca, grants from Astellas Pharma, grants from Amgen Astellas BioPharma, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Chugai Pharmaceutical, grants and personal fees from Daiichi Sankyo, grants from Eisai, grants and personal fees from Kyowa Hakko Kirin, grants and personal fees from MSD, grants and personal fees from Merck Serono, grants and personal fees from Novartis Pharma, grants and personal fees from ONO Pharmaceutical, grants and personal fees from Pfizer, grants and personal fees from Taiho, grants and personal fees from Takeda Pharmaceutical, and grants from Janssen Pharmaceutical, outside the submitted work. None of the other authors has any conflict of interest to declare.

: The study was conducted with the approval of the Institutional Review Boards of the National Cancer Center. The IRB approval number for this study was 2016-125. All the methods were performed in accordance with the approved guidelines.

: All the specimens were collected after obtaining written comprehensive informed consent from the patients.